SEP
CRBU icon

Signature Equity Partners’s Caribou Biosciences CRBU Stock Holding History

Signature Equity Partners’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-177
Closed -$336 – 1593
2026
Q1 		$336 Hold
177
– – ﹤0.01% 1427
2025
Q4 		$281 Buy
+177
New +$372 ﹤0.01% 1602

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Signature Equity Partners's CRBU Position: Q2 2026 in Review

Signature Equity Partners sold out of Caribou Biosciences (CRBU) in Q2 2026, closing a stake of 177 shares — an estimated $336 sold.

Signature Equity Partners first reported a position in CRBU in Q4 2025 and held it in 2 quarters. The position peaked at $336 in Q1 2026. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Signature Equity Partners reported no remaining Caribou Biosciences position as of Q2 2026 after selling out during the quarter.
  • Signature Equity Partners sold 177 Caribou Biosciences shares in Q2 2026, an estimated $336.
  • Signature Equity Partners first reported a position in Caribou Biosciences in Q4 2025 and held it in 2 quarters.
  • Signature Equity Partners's Caribou Biosciences position peaked at $336 in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.